Custom assay development for advanced drug discovery

Inaphaea is continuously validating cancer cell assays to measure cytotoxicity, cell metabolism and apoptosis markers against commercially available APIs.

Please contact us if you don’t see details for your experiment here.

Our immunoassays are ideal for elucidating MoAs of phenotypic effects by measuring a range of standard cytokines and signalling proteins from cells under stimulation conditions. More assays are being validated, so check back for further details.

Provided by our collaboration partner Physiomics, data generated by Inaphaea may be seamlessly integrated into the Physiomics modelling capability for advanced data interpretation.

Provided by our collaboration partner Agility Life Sciences, formulation development may be seamlessly integrated into Inaphaea’s cell based assays.  Enabling confirmation that your molecule is appropriate for our studies; and confirming your new formulation remains bioactive.

Provided by our collaboration partner, Inspiralis, access easy-to-use assay kits and their contract research services to study DNA-modifying enzyme activity. These services include compound screening (hit identifications), IC₅₀s to evaluate the outcomes of hit-to-lead and lead optimisation endeavours, mode of action studies and custom protein production.

Ignota Labs specialises in drug toxicity prediction using AI. Their services combine the best of technology and people with expert scientists operating world-leading AI tools. Their tools provide complex machine-learning outputs, which are distilled by expert scientists into powerful insights and guidance to support your drug discovery programme.

Our collaboration partner DefiniGEN can provide technology to revolutionise liver models for efficacy and toxicology screening, utilising a platform that enables the large-scale generation of hepatocyte-like cells (Opti-Heps) with functional relevance comparable to human primary cells.

Our partner HistologiX is a leading GLP/GCP compliant CRO supporting tissue based evaluation of your biomarkers.  Their experienced scientific team provides specialist histology, immunohistochemistry (IHC) including multiplex immunofluorescence (IF), multiplex in situ hybridisation (ISH) using RNAScope, digital pathology and image analysis.

They provide an excellent quality technical service supporting biomarker evaluation of cutting-edge therapeutics including cell and gene therapies, oncolytic viruses, therapeutic antibodies, small molecules, and RNA modifying enzymes.